Global Choroidal Neovascularization (CNV) Market 2014-2018 adds report Global Choroidal Neovascularization (CNV) Market 2014-2018 to its store. The current competition in the Global CNV market is strong as the available treatment options and marketed products have been successful in meeting the market requirement, while treating the underlying cause of the disease. The current market drugs include Lucentis, approved for CNV associated with wet AMD; Macugen, approved for CNV associated with wet AMD; and Visudyne, approved for CNV associated with wet AMD, presumed ocular histoplasmosis, and pathologic myopia. Apart from these, Avastin, which is currently used as an off-label drug has gradually captured a major share of the market. In addition, the CNV pipeline seems to be promising with various molecules in the development phase. These products are expected to meet the unmet needs in the market and will provide physicians with a wider choice in treating CNV.

According to the report, the Global CNV market is driven by several factors, of which high patient and physician satisfaction is one of the major drivers. High patient and physician satisfaction has resulted in increased demand for CNV treatment therapies.

Analysts forecast the Global CNV market will grow at a CAGR of 6.77 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global CNV market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of CNV

Global CNV Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global CNV market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Purchase Report Directly @

Key Regions
• Americas

Analyst recognizes the following companies as the key players in Global Choroidal Neovascularization (CNV) Market: Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Affitech A/S, Allergan Inc., Chengdu Kanghong Biotech Co. Ltd., Gilead Sciences Inc., Lpath Inc., Mat Biopharma SAS, Pfizer Inc., Promedior Inc., QLT Inc., Quark Pharmaceuticals Inc., Resolvyx Pharmaceuticals Inc., Sanwa Kagaku Kenkyusho Co. Ltd., Valeant Pharmaceuticals International Inc.

Key Market Driver
• High Patient and Physician Satisfaction.

Key Market Challenge
• High Cost of Treatment.

Key Market Trend
• Strong Competition in the Market.

Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

About Us: is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on and we would be happy to help you find the business intelligence that you need. Not limited to the Pharmaceuticals Market offers research studies on agriculture, consumer goods, environment, advanced materials, public sector, food and beverages, energy and power, medical devices, healthcare, automotive, manufacturing & construction, semiconductor and electronics, IT & telecommunication, pharmaceuticals, retail, water, banking and financial services , advanced materials and much more.